**Curriculum Vitae**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| (Photo) | **First name**  (Given name) | Brian | | | |
| **Last name**  (Family name) | Tomlinson | | | |
| **Affiliation** | Macau University of Science & Technology | | | |
| **Position & Title** | Professor, Faculty of Medicine | | | |
| **Education and Training** | | | | | |
| **Completion date**  **(MM/YYYY)** | **Institution / Location** | | **Degree**  ***(if applicable)*** | | **Field of study** |
| 1970 | University of London, UK. | | B.Sc. | | Medical Sciences |
| 1973 | University of London, UK. | | MB.BS. | | Medicine |
| 1993 | University of London, UK. | | M.D | | Medicine |
|  |  | |  | |  |
|  |  | |  | |  |
| **Employment and Position** | | | | | |
| **Period** | **Affiliation** | | | **Position** | |
| 2007~2015 | Chinese University of Hong Kong, Hong Kong. | | | Chair Professor of Medicine and Therapeutics | |
| 2015~2019 | Chinese University of Hong Kong, Hong Kong. | | | Adjunct Professor of Medicine and Therapeutics | |
| 2019~present | Faculty of Medicine, Macau University of Science & Technology | | | Professor, Faculty of Medicine | |
|  |  | | |  | |
|  |  | | |  | |
| **Important Publications (Up to 5)** | | | | | |
| Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Vallejo-Vaz AJ, et al. Lancet. 2021: 398 (10312):1713-1725. | | | | | |
| CYP2C19 Loss-of-function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 Diabetes. Wang K, Yang A, Shi M, Tam CCH, Lau ESH, Fan B, Lim CKP, Lee HM, Kong APS, Luk AOY, Tomlinson B, Ma RCW, Chan JCN and Chow E. Clin Pharmacol Ther. 2022:111(2):461-469. | | | | | |
| Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes. Goodrich JK et al. Nat Commun. 2021;12:3505. | | | | | |
| Familial Hypercholesterolemia in Asia Pacific: A Review of Epidemiology, Diagnosis, and Management in the Region. Kalra S, Chen Z, Deerochanawong C, Shyu KG, Tan RS, Tomlinson B and Yeh HI. J Atheroscler Thromb. 2021;28:417-434. | | | | | |
| Personalized medicine in lipid-modifying therapy. Tomlinson B, Lin CH, Chan P and Lam CW. Per Med. 2021;18:185-203. | | | | | |
| **Awards and Honors** | | | | | |
| Fellow of the Hong Kong Academy of Medicine (Medicine) 1993  Fellow of the Royal College of Physicians of London, 1994  Fellow of the Royal College of Physicians of Edinburgh, 1994  Fellow of the American College of Clinical Pharmacology, 1996  Fellow of the American College of Physicians, 1997  Fellow of the Hong Kong College of Cardiology, 1997  Fellow of the Royal College of Physicians and Surgeons of Glasgow, 2000 | | | | | |
| **Research Interests** | | | | | |
| Clinical and research interests include the clinical pharmacology, toxicology and pharmacogenetics of drugs, particularly in the cardiovascular field, and the pathogenesis and treatment of hyperlipidaemia, hypertension, the metabolic syndrome and diabetes with a particular interest in familial hypercholesterolaemia. | | | | | |